CAPA Slams Tillis/Coons Legislation As A Favor For Big Pharma To Protect Drug Monopolies

Coalition calls on Congress to oppose “poison pill” bill that would undo significant Supreme Court rulings on patent abuse and ultimately lead to increased prescription drug prices and reduced access to life-saving treatments


WASHINGTON, D.C. –  The Coalition Against Patent Abuse, a diverse coalition of healthcare providers, consumer groups, patient advocacy organizations, free market advocates and others released the following statement today in response to legislation proposed by U.S. Senators Thom Tillis and Chris Coons to amend Section 101 of the Patent Act which would undo decades of Supreme Court precedent in combating patent abuse by major drug companies. The following statements are attributable to Matthew Lane, Executive Director of the Coalition Against Patent Abuse.

“Every American struggling with rising prescription drug costs should be deeply concerned with this latest effort to undo decades of Supreme Court case law on patent abuse and make a bad situation for patients even worse. This bill, which claims to promote innovation, will result in more monopolies for Big Pharma, raise prescription drug prices even higher, reduce access and choice for treatments and disincentivize research and development.

“Legislation like this emboldens and empowers Big Pharma at the expense of everyday Americans. At a time when American patients are paying 65% more than citizens of other Western countries for the exact same prescription drugs, we need to look for ways to foster competition and innovation instead of enabling Big Pharma’s patent abuse.

“We strongly urge Congress to reject this harmful and counterproductive legislation. Our Coalition looks forward to working with Congress to find real solutions that will promote innovation, lower medical costs for patients and end Big Pharma’s rampant abuse of the patent system.”

CAPA Members testifying during the hearings of the Senate Subcommittee on Intellectual Property this week will include Jeff Francer, General Counsel For the Association for Accessible Medicines and Director, Technology & Innovation and Charles Duan, Senior Fellow for the R Street Institute. 

For more information, please visit


About CAPA

The Coalition Against Patent Abuse are healthcare providers, consumer groups, patient advocacy organizations, free market advocates, employers, and others fighting abuses of the patent system that can extend government-granted monopolies that illegitimately keep drug prices high for years, or even decades. Our members include the following groups and organizations: America’s Health Insurance Plans, Association for Accessible Medicines, Blue Cross Blue Shield, Campaign for Sustainable Rx Pricing, Citizen Outreach, Consumer Action, Innovation Defense Fund, Institute for Liberty, Kaiser Permanente, Knowledge Ecology International, Lincoln Network, R Street Institute, Society for Patient Centered Orthopedics, and U.S. Public Interest Research Group.